News New Teva CEO axes R&D chief Hayden in boardroom shakeup R&D chief Michael Hayden to leave at year end.
News Teva sells women's health division to tackle $35bn debts Teva has sold its women’s health business in order to pay off some of its $35 billion in debts built up in acquiring Allergan’s generics business.
News Bidders lining up for Teva women's health unit Allergan generics buyout left Teva with $35m debts
News FDA's Gottlieb reveals plans to tackle generic price abuses Tackling high drug prices is priority for Trump administrations.
News Teva's CEO Vigodman steps down Firm searches for new leader, chairman takes over on interim basis.
Views & Analysis Making the case for pharmaceutical IP management IP management can protect pharma companies’ investments and future R&D.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.